STIMIT
About:
STIMIT enables extended local delivery of cancer immunotherapy in the context of tumor resection.
Website: https://stimittx.com/
Top Investors: Alumni Ventures, DHVC
Description:
STIMIT's proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.
$20.6M
Cambridge, Massachusetts, United States
2018-01-01
info(AT)stimittx.com
Michael Goldberg
1-10
2020-12-03
Private
© 2025 bioDAO.ai